Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
Journal for immunotherapy of cancer (2022)
There is great interest in finding ways to identify patients who will develop toxicity to cancer therapies. This has become especially pressing in the era of immune therapy, where toxicity can be long-lasting and life-altering, and primarily comes in the form of immune-related adverse effects (irAEs). Treatment with the first drugs in this class, anti-programmed death 1 (anti-PD1)/programmed death-ligand 1 (PDL1) checkpoint therapies, results in grade 2 or higher irAEs in up to 25%–30% of patients, which occur most commonly within the first 6 months of treatment and can include arthralgias, rash, pruritus, pneumonitis, diarrhea and/or colitis, hepatitis, and endocrinopathies. We tested the hypothesis that germline microRNA pathway functional variants, known to predict altered systemic stress responses to cancer therapies, would predict irAEs in patients across cancer types.
Recommended citation: Weidhaas, J., Marco, N., Scheffler, A. W., Kalbasi, A., Wilenius, K., Rietdorf, E., ... & Telesca, D. (2022). Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. Journal for immunotherapy of cancer, 10(2).